Dear Mr. Leber:

Please refer to your Supplemental New Drug Applications (sNDA) dated March 19, 2014, received March 19, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

<table>
<thead>
<tr>
<th>Application</th>
<th>Drug Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 021168/S-028</td>
<td>Depakote ER (divalproex sodium) Extended Release Tablets</td>
</tr>
<tr>
<td>NDA 018081/S-060</td>
<td>Depakene (valproic acid) Capsules</td>
</tr>
<tr>
<td>NDA 019680/S-039</td>
<td>Depakote Sprinkle Capsules (divalproex sodium coated particles in capsules)</td>
</tr>
<tr>
<td>NDA 018082/S-043</td>
<td>Depakene (valproic acid) Oral Solution</td>
</tr>
<tr>
<td>NDA 018723/S-052</td>
<td>Depakote (divalproex sodium) Delayed Release Tablets</td>
</tr>
<tr>
<td>NDA 020593/S-030</td>
<td>Depacon (valproate sodium) Injection</td>
</tr>
</tbody>
</table>

These “Changes Being Effected” supplemental new drug applications provide for revised language to Section 7.2, as specified below, and consistent with the Agency’s letter dated October 24, 2013:

**Section 7.2 Effects of Valproate on Other Drugs**

Drugs for which either no interaction or a likely clinically unimportant interaction has been observed
Olanzapine

No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and Olanzapine (5mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [link to Form FDA 2253]. Information and Instructions for completing the form can be found at [link to Instructions for Form FDA 2253]. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see [link to OPDP submission information].

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Sharonjit Sagoo, Pharm.D., Regulatory Project Manager, at sharonjit.sagoo@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
CAPT, USPHS
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
06/09/2014